Alkem Laboratories Ltd, a leading Indian pharmaceutical company, has been hit with a new Goods and Services Tax (GST) demand of ₹13.7 million. This latest development adds to the company's ongoing tax challenges, following a ₹62 crore GST demand received in February 2025. The new order, details of which are yet to be fully disclosed, is likely to be contested by Alkem. This pattern of tax disputes highlights the complex regulatory environment facing pharmaceutical companies in India. Alkem's response to these recurring tax demands will be closely watched by industry observers, as it could set precedents for how pharmaceutical firms navigate GST compliance issues in the future.
Source: Economic Times